Frontlight ResearchEarly access
CompletedPhase 2
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Belgium, France, Germany, Hungary, and Spain7 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 20 people enrolled
- Started
- 22 Nov 2022
- Ended
- 25 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TIN816 70 mg lyophilisate powder
- Placebo
- Record updated
- 4 December 2025
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Signed informed consent must be obtained prior to participation in the study
- ≥ 18 and ≤ 85 years of age
- Admitted to ICU or intermediate/HDU
- Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:; Suspected or confirmed infection SOFA score of 2 or more (excluding renal component)
- Diagnosis of AKI Stage 1 or greater per the following criterion at randomization :; An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference creatinine baseline; For hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI should be used as reference baseline, otherwise, baseline serum creatinine in the following order of preference:; Median value within 3 months of the hospital admission. If not available:; Median value between 3 and 6 months prior to hospital admission. If not available:; At hospital admission
Who cannot take part
- Receiving RRT or a decision has been made to initiate RRT within 24 hours of admission
- AKI diagnosis according to the AKI inclusion criteria for a period longer than 48 hours prior to study drug administration
- Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization
- Patients who are on dual antiplatelet therapy
- Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable)
- Use of other investigational drugs within 5 half-lives of enrollment within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations
- Not expected to survive for 30 days due to medical conditions other than SA-AKI
- AKI is most likely attributable to causes other than sepsis such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides), other medical conditions (e.g. heart failure, liver failure, acute abdominal aortic aneurysm, dissection, renal artery stenosis) or urinary obstruction
- Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN)
- Acute pancreatitis with no established source of infection
- Sepsis attributed to confirmed COVID-19
- History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes
- Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement
- History of CKD with a documented estimated GFR <45 ml/min prior to development of AKI
- Presence of AKI for a period longer than 48 hours prior to study drug administration as suggested by clinical manifestations, e.g., prolonged oliguria or severe renal dysfunction (eg, serum creatinine > 4 mg/dL) on admission without a history of CKD
- Patients who are thrombocytopenic at screening (Platelet count <100,000 microliter) or other high risk for bleeding in the opinion of the investigator
- Immunosuppressed patients:; History of immunodeficiency diseases or known HIV test positive. Is receiving immunosuppressant treatment or is on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with hydrocortisone (e.g., 3 × 100 mg) can be included
- Active hepatitis (defined as (a) abnormal liver enzymes (Alanine aminotransferase (ALT), Gamma-glutamyl transferase (GGT), ALP > 3x Upper Limit of Normal (ULN) or (b)) for active hepatitis B or C infection, a positive Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) serology or patients with advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)
- Not expected to survive for 24 hours
- Weight is less than 40 kg or more than 125 kg
- Has life support limitations (eg, do not resuscitate, do not dialyze, do not intubate)
- Patients who are post-nephrectomy
- Burns requiring ICU treatment
- Women with a positive pregnancy test, pregnancy or breast feeding
- Women of child-bearing potential
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
The 2 groups in the trial
- TIN816Treatment being tested
Administered as an intravenous dose
Treatment: TIN816 70 mg lyophilisate powder
- PlaceboPlacebo, for comparison
0.9% sterile sodium chloride solution administered as an intravenous dose
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Participant and Investigator-blinded, Randomized, Placebo-controlled Phase 2a Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
- Record updated
- 4 December 2025